New expectations are bringing about significant changes in Process Validation approaches. As a result,
companies are struggling to understand how these expectations can be transformed into practical actions and
business processes.
ISPE is offering this interactive, topic-specific Conference on how to implement these changes into your
business, gain clarity and be compliant with the FDA Process Validation Guidance.
Subject Matter experts will offer insight around the Guide and suggest practical approaches to satisfying
these requirements. A question and answer session will follow, offering an opportunity for you to gain
clarity around the Guide.
Through small group exercises and discussion forums, you will be able to practice application of the
lifecycle approach and discuss approaches from your colleagues. These exercises will focus on acceptance
criteria, sampling plans, determining batches and the elements of a heightened monitoring plan. Larger group
sessions will provide additional opportunity for benchmarking approaches.
Leader
- Joanne Barrick, Advisor, Global
Validation Support, Eli Lilly & Co., USA
Speakers
- Dave Dolgin, Sr. Quality Program
Manager, Abbott Laboratories, USA
- Kurtis Epp (Invited), Senior
Manager, Manufacturing, BioTechLogic, USA
- Joe Famulare, Sr. Director,
Genetech, USA
- Jeff Flemming, Pfizer, Inc., USA
- Karthik Iyer, Senior Policy
Advisor, FDA, USA
- John Lepore, Sr.
Director-Chemical Process Development and Commercialization, Merck, Inc., USA
- Catherine McHugh (Invited),
Irish Medicines Board
- Grace McNally, Consumer Safety
Officer, FDA, USA
- Anne Renton, Quality
Consultant, Eli Lilly & Co., USA
- Mark Varney, Sr. Quality
Consultant, Abbott Laboratories, USA